ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Silence Therapeutics PLC

Silence Therapeutics PLC (SLN)

9,90
-0,25
(-2,46%)
Beim Schlusskurs: 08 Juli 10:00PM
9,90
0,00
( 0,00% )
Nach Börsenschluss: 10:14PM

Silence Therapeutics PLC (SLN) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Wichtige Statistiken und Details

Current Price
9,90
( -2,46% )
Gebot
9,62
Fragen
10,80
Volumen
494.245
Durchschnittliches Volumen (3 Mio.)
US$ 396.437
Finanzvolumen
US$ 4.789.211
9,4234 Tagesbereich 10,205
4,19 52-Wochen-Bereich 11,0599
Marktkapitalisierung
Unternehmenswert
420,819M
Handelsende
10,15
Handelsbeginn
10,05
Letzte Trade
1
@
9.95
Letzter Handelszeitpunkt
22:10:04
VWAP
9,69
Erlöse (LTM)
839k
Nettogewinn (LTM)
-75,04M
Ausgegebene Aktien
47.233.949
Streubesitz (%)
54,87%
Institutioneller Besitz (%)
43,07%
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-6,54
Kurs-Umsatz-Verhältnis (KUV)
584,94
Gewinn pro Aktie (EPS)
-1,59
Beta
1,38

Über Silence Therapeutics PLC

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran ... Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
London, United Kingdom
Gegründet
1994
Silence Therapeutics PLC is listed in the Healthcare sector of the NASDAQ with ticker SLN. The last closing price for Silence Therapeutics was US$10,15. Over the last year, Silence Therapeutics shares have traded in a share price range of US$ 4,19 to US$ 11,0599.

Silence Therapeutics currently has 47.233.949 shares in issue. The market capitalisation of Silence Therapeutics is US$467,62 million. Silence Therapeutics has a price to earnings ratio (PE ratio) of -6.54.

SLN Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.92-8.5027726432510.8211.05999.965302810.40563703DR
43.9967.51269035535.9111.05995.916663909.27223115DR
123.7560.97560975616.1511.05995.743927598.27380177DR
264.170.68965517245.811.05994.193471887.0346229DR
524.0669.52054794525.8411.05994.192539496.78052283DR
1564.0769.81132075475.8327.721.9722817410.08876836DR
260-16.93-63.101006336226.8327.721.9715268410.32932681DR

SLN - Frequently Asked Questions (FAQ)

What is the current Silence Therapeutics PLC share price?
The current share price of Silence Therapeutics PLC is US$ 9,90
How many Silence Therapeutics PLC shares are in issue?
Silence Therapeutics PLC has 47.233.949 shares in issue
What is the market cap of Silence Therapeutics PLC?
The market capitalisation of Silence Therapeutics PLC is USD 467,62M
What is the 1 year trading range for Silence Therapeutics PLC share price?
Silence Therapeutics PLC has traded in the range of US$ 4,19 to US$ 11,0599 during the past year
What is the PE ratio of Silence Therapeutics PLC?
The price to earnings ratio of Silence Therapeutics PLC is -6,54
What is the cash to sales ratio of Silence Therapeutics PLC?
The cash to sales ratio of Silence Therapeutics PLC is 584,94
What is the registered address of Silence Therapeutics PLC?
The registered address for Silence Therapeutics PLC is 12 Hammersmith Grove, London, Greater London, W6 7AP
What is the Silence Therapeutics PLC website address?
The website address for Silence Therapeutics PLC is www.silence-therapeutics.com
Which industry sector does Silence Therapeutics PLC operate in?
Silence Therapeutics PLC operates in the Biotechnology & Life Sciences sector

SLN Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen